Semaglutide Linked to Fewer Hospital Stays in Bipolar Disorder Study

A large observational study from Sweden is drawing attention to a possible mental health signal from semaglutide, the active ingredient in Ozempic and Wegovy. Researchers from Griffith University analyzed nationwide data spanning 15 years and covering nearly 15,000 people living with bipolar disorder who had been prescribed GLP-1 medications, according to a Griffith University summary published on ScienceDaily.

The team compared hospitalization patterns within the same individuals during periods when they were taking semaglutide versus periods when they were not. They found a 21 percent lower risk of psychiatric hospitalization during semaglutide use. Notably, this pattern did not hold for every drug in the class. Liraglutide and dulaglutide showed no similar association, suggesting any benefit may not be shared across all GLP-1 medicines.

The researchers propose that GLP-1 signaling could influence inflammation and cellular stress pathways linked to bipolar disorder, potentially supporting mood stability. That mechanism remains speculative. This is an observational cohort study, not a randomized controlled trial, so it cannot establish that semaglutide directly causes fewer relapses. Lead researcher Mark Taylor said he hopes the findings prompt a randomized trial to test the association more rigorously. Semaglutide remains an approved medication for diabetes and weight management, not a treatment for bipolar disorder.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.